While Caplin Point Laboratories and Gland Pharma, post-market hours on Tuesday, informed the exchanges of the results of the regulatory authorities’ good manufacturing practices (GMP) inspections at their facilities, Nephrocare Health Services updated on an acquisition by its overseas step-down subsidiary.
Caplin Point Laboratories
Caplin Point Laboratories on Monday, September 1, informed the stock exchanges that the manufacturing unit of its subsidiary COL, located in Tiruvallur district, Tamil Nadu, has received confirmation of compliance with good manufacturing practices (GMP) from the National Institute for the Surveillance of Food and Drugs (INVIMA).
INVIMA is the regulatory authority designated by the ministry of health and social protection of the Republic of Colombia.
Caplin Point, in an exchange filing, stated that INVIMA had concluded that COL complies with the GMP requirements for the manufacture of the oncology drug products — lyophilized powder for injections (in vials) in the sterile category and tablets (coated and uncoated), hard capsules in the non-sterile category.
It added that it expects to receive the formal certificate from INVIMA in due course.
Shares of Caplin Point ended 8% higher on Tuesday at ₹2,720, extending their year-to-date advance to 51.2%.
Gland Pharma
Gland Pharma on Tuesday, September 1, said the US Food and Drug Administration (USFDA) has concluded its routine good manufacturing practice (GMP) inspection at the firm’s VSEZ sterile oncology formulations facility and API facility.
It said the inspection was concluded with zero Form 483 observations.
The US drug regulator had conducted the inspection at the facilities between August 24, 2026 and September 1, 2026.
Shares of Gland Pharma ended the previous session 0.7% lower at ₹2,864.5 apiece. The stock has gained 11% in the past month and has gained 67% this year, so far.
Nephrocare Health Services
The company said its overseas step-down subsidiary Nephroplus Health Services Kazakhstan LLP (NPHSK LLP) on Tuesday, September 1, 2026, entered a sale and purchase agreement with the seller Ms Aizhan Slambekovna Zhambulova for the acquisition of 100% participatory interest in the charter capital of the target entity ‘Dialysis Center Almaty” LLP — a limited liability partnership incorporated under the laws of the Republic of Kazakhstan.
The aggregate consideration payable for the acquisition is KZT 561.66 million, which is approximately ₹11.63 crore), the company said in an exchange filing. The same is subject to downward adjustments as may be appliable in accordance with the terms of the share purchase agreement, it added.
Once the transaction is completed NPHSK LLP will hold 100% participatory interest in the target entity and consequently the latter will become an overseas step-down subsidiary of the company, it said.
The company added that the acquisition is in line with its strategy of expanding its dialysis services network in international markets and will strengthen its presence in Kazakhstan further.
Shares of Nephrocare Health Services ended the previous session 0.7% up at ₹688 apiece. The stock has gained 51% this year, so far.
Also Read: Welspun Corp shares in focus after Jordan pipe manufacturing JV MoU; stock up 220% in 2026
